港股異動 | 中芯國際午後上升超9%,刷新歷史新高,今天提交註冊擬科創板上市
uSMART友信智投6月23日消息,週二港股,中芯國際午後上升幅度擴大,截至北京時間15時33分,中芯國際上升9.09%,報26.4港元,股價創上市以來新高,股價本月累上升56.77%,年初至今累上升121.11%。
消息面上,上交所今天公告稱,科創板擬上市公司中芯國際積體電路製造有限公司提交註冊。中芯國際昨日回復上市委會議意見落實函表示,公司報告期內總體產能利用率和產能逐年上升,未識別出經濟績效下滑跡象。此外,雖然28納米制程積體電路晶圓代工業務毛利率持續為負,但並不構成相關固定資產和在建工程減值的跡象。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.